PTC Therapeutics (PTCT) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue was $187 million, with strong performance across marketed products and robust cash reserves, though net product revenue declined 24% year-over-year to $133.2 million due to lower Translarna and Emflaza sales after Emflaza's loss of exclusivity and timing of government orders.

• Royalty revenue from Evrysdi increased 44% year-over-year to $53.2 million, driven by higher global sales.

• Net loss for Q2 2024 was $99.2 million, an improvement from $198.9 million in Q2 2023, reflecting lower R&D and SG&A expenses and absence of prior year intangible asset impairments.

• Submitted three major regulatory filings: NDA for sepiapterin (PKU), NDA resubmission for Translarna (DMD), and BLA for Upstaza (AADC deficiency), with all interim clinical and regulatory milestones met.

• Completed the sale of the gene therapy manufacturing business, receiving upfront cash and reducing ongoing expenses.

Financial highlights

• Q2 2024 total revenue: $187 million; DMD franchise revenue: $118 million; Emflaza: $47.3 million; Translarna: $70.4 million; royalty revenue from Evrysdi: $53.2 million.

• Operating expenses for Q2 2024 were $226.9 million, down from $423.4 million year-over-year.

• Non-GAAP R&D expense: $123 million (excluding $9 million stock-based comp); SG&A expense: $60 million (excluding $10 million stock-based comp).

• Net loss per share improved to $(1.29) from $(2.66) year-over-year.

• Cash, cash equivalents, and marketable securities: $1.09 billion as of June 30, 2024.

Outlook and guidance

• 2024 total revenue guidance raised to $700–$750 million, driven by sustained Translarna revenue in Europe and strong portfolio performance.

• OpEx guidance for 2024 maintained, with infrastructure in place to support multiple upcoming launches.

• Management expects continued significant expenses for commercialization, R&D, and regulatory activities, including ongoing efforts for Translarna, sepiapterin, and Upstaza.

• Top-line results from the CARDINAL ALS trial expected in Q4 2024; NDA submission for vatiquinone in Friedreich ataxia expected by year-end.

• Cash flows from product sales, royalties, and existing liquidity are expected to fund operations for at least the next twelve months.